TSH Stimulation before PET/CT as Our Frenemy in Detecting Thyroid Cancer Metastases—Final Results of a Retrospective Analysis
Authors:
- Maciej KołodziejMKMaciej Kołodziej
- Marek SaracynMSMarek Saracyn
- Arkadiusz LubasALArkadiusz Lubas
- Dorota Brodowska-KaniaDBDorota Brodowska-Kania
- Andrzej MazurekAMAndrzej Mazurek
- Mirosław DziukMDMirosław Dziuk
- Adam Daniel DurmaADAdam Daniel Durma
- Stanisław NiemczykStanisław Niemczyk
- Grzegorz KamińskiGKGrzegorz Kamiński
Open Access
Abstract
Introduction: Non-iodine avid metastases of differentiated thyroid cancer (DTC) can be found using PET/CT with a fluorine-18-labeled glucose analog ([18F]FDG). There are ongoing discussions on the appropriateness of using exogenous thyrotropin (TSH) stimulation before this examination. Material and Methods: In a retrospective study, 73 PET/CT scans with [18F]FDG performed after exogenous stimulation with recombinant human TSH (rhTSH) and without such stimulation were analyzed. All analyzed patients were suspected of having non-iodine-avid foci of DTC. Results: The stimulation with rhTSH before the PET/CT did not affect the percentage of positive results: 37.5% (18/48) with rhTSH and 40% (10/25) without rhTSH (p = 0.83). The analysis of the ROC curves established the cut-off thyroglobulin point for a positive PET/CT result separately for both subgroups. There was no statistically significant difference between obtaining a positive PET/CT result and the baseline thyroglobulin concentration (both stimulated and unstimulated). The exogenous stimulation of TSH prior to the PET/CT had no effect on the [18F]FDG uptake in the PET/CT lesions. Conclusions: PET/CT with [18F]FDG remains a useful method for the diagnosis of non-iodine-avid DTC lesions; in the presented group, a positive effect of rhTSH stimulation on the number of DTC foci visible in the PET/CT was found, but without affecting its effectiveness.Keywords
Funding Information
- Military Institute of Medicine—National Research Institute
This publication has 23 references indexed in Scilit:
- Usefulness of PET‐CT scan in recurrent thyroid cancerWorld Journal of Otorhinolaryngology - Head and Neck Surgery, 2020
- Head-to-head comparison of F-18 FDG PET/CT in radioidine refractory thyroid cancer patients with elevated versus suppressed TSH levels a pilot studyHeliyon, 2020
- Optimal threshold of stimulated serum thyroglobulin level for 18F-FDG PET/CT imaging in patients with thyroid cancerCurrent Medical Science, 2017
- The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scanNuclear Medicine Communications, 2016
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative 131I whole body scan: evaluation by thyroglobulin levelAnnals of Nuclear Medicine, 2011
- Does Recombinant Human Thyrotropin-Stimulated Positron Emission Tomography with [18F]Fluoro-2-Deoxy- d -Glucose Improve Detection of Recurrence of Well-Differentiated Thyroid Carcinoma in Patients with Low Serum Thyroglobulin?Thyroid®, 2010
- The Added Benefit of a Dedicated Neck F-18 FDG PET-CT Imaging Protocol in Patients With Suspected Recurrent Differentiated Thyroid CarcinomaClinical Nuclear Medicine, 2008
- Influence of rhTSH on [18F]fluorodeoxyglucose uptake by differentiated thyroid carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998